RU2015120645A - Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) - Google Patents
Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) Download PDFInfo
- Publication number
- RU2015120645A RU2015120645A RU2015120645A RU2015120645A RU2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- oligonucleotide
- fgfr3
- oligonucleotide according
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
Claims (15)
1. Антисмысловой олигонуклеотид, длиной 8-25 нуклеотидов, включающий один или более аналогов нуклеотидов, который способен гибридизоваться по участку последовательности SEQ ID NO: 4, включающий положение нуклеотида 1394 последовательности SEQ ID NO: 4.
2. Олигонуклеотид по п. 1, который по меньшей мере на 80% идентичен олигонуклеотиду, выбранному из группы, состоящей из последовательностей SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 и SEQ ID NO: 14.
3. Олигонуклеотид по п. 1 или 2, который имеет длину 14-18 нуклеотидов.
4. Олигонуклеотид по п. 1, который предпочтительно модулирует экспрессию мутированной формы рецептора фактора роста фибробластов FGFR3 по сравнению с экспрессией рецептора FGFR3 дикого типа.
5. Олигонуклеотид по п. 1, выбранный из группы, состоящей из последовательностей SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 и SEQ ID NO: 25.
6. Олигонуклеотид по п. 1, в котором один или более аналогов нуклеотидов выбран из группы, состоящей из: звеньев запертой нуклеиновой кислоты (ЗНК); звеньев 2'-O-алкил-РНК, звеньев 2'-ОМе-РНК, звеньев 2'-амино-ДНК и звеньев 2'-фтор-ДНК.
7. Олигонуклеотид по п. 1, который включает два или более мономерных звеньев ЗНК.
8. Олигонуклеотид по п. 1, выбранный из группы, состоящей из последовательностей SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 и SEQ ID NO: 25.
9. Олигонуклеотид по п. 1, который включает SEQ ID NO: 21.
10. Конъюгат, включающий указанный олигонуклеотид по пп. 1-9 и по меньшей мере один ненуклеотидный фрагмент, ковалентно присоединенный к указанному олигонуклеотиду.
11. Применение олигонуклеотида по любому из пп. 1-9 или конъюгата по п. 10 для лечения состояния, связанного с аномальной экспрессией рецептора FGFR3, например, рака или хондродистрофии.
12. Способ снижения экспрессии мРНК FGFR3, включающий доставку к мРНК FGFR3 олигонуклеотида по любому из пп. 1-9 или конъюгата по п. 10, в условиях, подходящих для гибридизации указанной мРНК FGFR3 с указанным олигонуклеотидом, что приводит к снижению экспрессии мРНК FGFR3.
13. Способ снижения экспрессии in vitro мРНК FGFR3, включающий доставку к мРНК FGFR3 олигонуклеотида по любому из пп. 1-9 или конъюгата по п. 10, в условиях, подходящих для гибридизации указанной мРНК FGFR3 с указанным олигонуклеотидом, что приводит к снижению экспрессии мРНК FGFR3.
14. Способ лечения состояния, связанного с аномальной экспрессией рецептора FGFR3, включающий выбор пациента, у которого диагностировали указанное состояние, и введение такому пациенту олигонуклеотида по любому из пп. 1-9 или конъюгата по п. 10.
15. Фармацевтическая композиция, включающая олигонуклеотид по любому из пп. 1-9 или конъюгат по п. 10 и фармацевтически приемлемый разбавитель, носитель, растворитель, соль или адъювант.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729922P | 2012-11-26 | 2012-11-26 | |
US61/729,922 | 2012-11-26 | ||
PCT/EP2013/074552 WO2014080004A1 (en) | 2012-11-26 | 2013-11-25 | Compositions and methods for modulation of fgfr3 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015120645A true RU2015120645A (ru) | 2017-01-10 |
Family
ID=49639882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015120645A RU2015120645A (ru) | 2012-11-26 | 2013-11-25 | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) |
Country Status (12)
Country | Link |
---|---|
US (1) | US9725723B2 (ru) |
EP (1) | EP2922955B1 (ru) |
JP (1) | JP6463687B2 (ru) |
KR (1) | KR20150088305A (ru) |
CN (1) | CN104903448B (ru) |
BR (1) | BR112015012051A2 (ru) |
CA (1) | CA2889993A1 (ru) |
DK (1) | DK2922955T3 (ru) |
HK (1) | HK1208702A1 (ru) |
MX (1) | MX2015006289A (ru) |
RU (1) | RU2015120645A (ru) |
WO (1) | WO2014080004A1 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
CN104903448B (zh) | 2012-11-26 | 2017-07-11 | 罗氏创新中心哥本哈根有限公司 | 用于调节fgfr3的表达的组合物和方法 |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
KR20230152178A (ko) | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
FI3769765T3 (fi) | 2018-03-19 | 2024-05-15 | Taiho Pharmaceutical Co Ltd | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus |
JPWO2021153703A1 (ru) * | 2020-01-31 | 2021-08-05 | ||
WO2022211095A1 (ja) * | 2021-03-31 | 2022-10-06 | ルクサナバイオテク株式会社 | Fgfr3のアンチセンスオリゴヌクレオチド |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
EP2253639A1 (en) | 1997-09-12 | 2010-11-24 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US20030087854A1 (en) | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
US7427672B2 (en) | 2003-08-28 | 2008-09-23 | Takeshi Imanishi | Artificial nucleic acids of n-o bond crosslinkage type |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
AU2007211080B9 (en) | 2006-01-27 | 2012-05-03 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
ES2386578T3 (es) | 2006-05-05 | 2012-08-23 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de PCSK9 |
ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
EP2090127A2 (en) | 2006-10-30 | 2009-08-19 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
DK2176280T4 (en) | 2007-07-05 | 2015-07-20 | Isis Pharmaceuticals Inc | 6-Disubstituerede bicykliske nukleinsyreanaloge |
WO2009090182A1 (en) * | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
HUE061117T2 (hu) * | 2009-03-25 | 2023-05-28 | Genentech Inc | Anti-FGFR3 antitestek és eljárások alkalmazásukra |
WO2011139843A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
CN104903448B (zh) | 2012-11-26 | 2017-07-11 | 罗氏创新中心哥本哈根有限公司 | 用于调节fgfr3的表达的组合物和方法 |
US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2013
- 2013-11-25 CN CN201380061132.9A patent/CN104903448B/zh not_active Expired - Fee Related
- 2013-11-25 RU RU2015120645A patent/RU2015120645A/ru not_active Application Discontinuation
- 2013-11-25 BR BR112015012051A patent/BR112015012051A2/pt active Search and Examination
- 2013-11-25 US US14/647,430 patent/US9725723B2/en active Active
- 2013-11-25 EP EP13795243.8A patent/EP2922955B1/en not_active Not-in-force
- 2013-11-25 MX MX2015006289A patent/MX2015006289A/es unknown
- 2013-11-25 KR KR1020157016841A patent/KR20150088305A/ko not_active Application Discontinuation
- 2013-11-25 WO PCT/EP2013/074552 patent/WO2014080004A1/en active Application Filing
- 2013-11-25 JP JP2015543449A patent/JP6463687B2/ja not_active Expired - Fee Related
- 2013-11-25 CA CA2889993A patent/CA2889993A1/en not_active Abandoned
- 2013-11-25 DK DK13795243.8T patent/DK2922955T3/da active
-
2015
- 2015-09-21 HK HK15109264.3A patent/HK1208702A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2014080004A1 (en) | 2014-05-30 |
JP6463687B2 (ja) | 2019-02-06 |
DK2922955T3 (da) | 2019-05-13 |
US20150307886A1 (en) | 2015-10-29 |
HK1208702A1 (en) | 2016-03-11 |
JP2016501520A (ja) | 2016-01-21 |
KR20150088305A (ko) | 2015-07-31 |
CA2889993A1 (en) | 2014-05-30 |
MX2015006289A (es) | 2015-12-03 |
US9725723B2 (en) | 2017-08-08 |
EP2922955A1 (en) | 2015-09-30 |
CN104903448A (zh) | 2015-09-09 |
BR112015012051A2 (pt) | 2017-12-12 |
EP2922955B1 (en) | 2019-03-06 |
CN104903448B (zh) | 2017-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015120645A (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) | |
RU2681470C1 (ru) | Антисмысловые нуклеиновые кислоты | |
DK3118311T3 (en) | Antisense nucleic acid | |
JP6208349B2 (ja) | アンチセンス核酸 | |
RU2018119315A (ru) | Олигонуклеотиды для индуцирования отцовской экспрессии ube3a | |
HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
TWI725990B (zh) | 反義核酸 | |
JP2019512014A (ja) | がん診断法および治療法におけるpiRNAを使用する組成物および方法 | |
JP2016116520A5 (ru) | ||
JP2010526797A5 (ru) | ||
JP2013510561A5 (ru) | ||
JP2018512041A5 (ru) | ||
JP2010524486A5 (ru) | ||
TW201215408A (en) | Antisense nucleic acid | |
JP2008532477A5 (ru) | ||
JP2023158214A (ja) | Hif2αの遺伝子発現を阻害する組成物及び方法 | |
KR102417601B1 (ko) | Tgf-r 신호의 억제제로서의 안티센스-올리고뉴클레오티드 | |
JP2015511821A5 (ru) | ||
TN2015000079A1 (en) | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies | |
TW200927176A (en) | RNA antagonist compounds for the modulation of PIK3CA expression | |
KR20160098097A (ko) | 마이크로알앤에이 검출용 키트 및 방법 | |
EP3898975A2 (en) | Antisense oligonucleotides targeting card9 | |
JP2009502111A5 (ru) | ||
US11793828B2 (en) | MicroRNA 19A/19B for use in treating a pathological condition associated with bone loss or reduced muscle function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20181126 |